文献速递主动脉疾病

结缔组织病患者行胸主动脉腔内修复术并非确定性治疗选择

Thoracic endovascular aortic repair in connective tissue disease patients is not a definitive option.
PubMed 文献 · J Vasc Surg · 2024-11-30

该单中心回顾性研究纳入2014年2月至2021年4月因胸腹主动脉瘤或主动脉夹层行胸主动脉腔内修复术(TEVAR)的40例结缔组织病(CTD)患者,评估其耐久性、并发症和结局。结果显示TEVAR可安全实施,但主动脉相关并发症和再干预风险高,再干预和开放转换多发生在术后1年内。

要点

  • 40例CTD患者行TEVAR,62.5%需再干预,再干预中位时间9.1个月。
  • 1年免于开放转换率67.2%,2年和3年均为59.7%。
  • 1、2、3年免于再干预率分别为49.8%、36.0%、30.0%。

核心结论

  • 本研究提示CTD患者行TEVAR可安全实施,但主动脉相关并发症和再干预风险高,再干预和开放转换常见且多发生在1年内,在获得更耐久结局前TEVAR应限定用于该人群。

研究设计与样本

  • 单中心回顾性研究,纳入2014年2月至2021年4月因胸腹主动脉瘤或主动脉夹层行TEVAR的40例CTD患者,CTD包括马方综合征、Loeys-Dietz综合征及非特异性CTD相关诊断。

主要发现

  • 中位年龄53岁,女性占52.5%;马方综合征占57.5%,Loeys-Dietz综合征占2.5%,非特异性或其他CTD占40%;32例(80%)有既往主动脉干预史。
  • 胸主动脉瘤占52.5%,夹层占82.5%;平均最大胸主动脉直径为55.2 mm;术后1个月内死亡2例。
  • 剩余38例中,71.1%发生动脉瘤相关并发症,包括81.5%的动脉瘤样退变和33.3%的内漏。
  • 总体62.5%需再干预,再干预中位时间9.1个月;再干预类型包括再次TEVAR/延伸32%、升主动脉/弓部修复24%、开放胸腹主动脉修复56%、假腔栓塞16%。
  • 1年免于开放转换率为67.2%,2年和3年均为59.7%;1、2、3年免于再干预率分别为49.8%、36.0%、30.0%。

临床怎么用

  • 作者认为,在获得更耐久结局前,TEVAR应限定用于CTD患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Open surgery is the gold standard for patients a connective tissue disorder (CTD). Thoracic endovascular aortic repair (TEVAR) is used in emergencies and patient-specific situations. Limited data on durability of TEVAR in patients with CTD exist. The purpose of this study was to investigate the durability, complications, and outcomes of TEVAR in patients with CTD. METHODS: This single-center retrospective study included 40 patients with CTD who underwent TEVAR for thoracoabdominal aortic aneurysm or aortic dissection from February 2014 to April 2021. CTDs included Marfan syndrome, Loey-Dietz syndrome, and nonspecific CTD-related diagnoses. Primary outcomes included aortic-related morbidities, time to and type of postoperative reinterventions, and time to open/hybrid conversion. Time to conversion and reintervention was calculated using Kaplan-Meier estimation. Predictors of reintervention and open/hybrid conversion were evaluated using Cox proportional hazards models. RESULTS: The median age was 53 years with 52.5% of the patients being female. Marfan syndrome was diagnosed in 57.5%, Loey-Dietz syndrome in 2.5%, and 40% had a diagnosed nonspecific or other CTD. Thirty-two (80%) had prior aortic interventions. Thoracic aneurysm existed in 52.5% and dissection in 82.5%. The average maximum thoracic aortic diameter was 55.2 mm. There were two mortalities within the first month. Of the remaining 38 patients, 71.1% had aneurysm-related morbidities, including 81.5% with aneurysmal degeneration and 33.3% with endoleak. Overall, 62.5% required reintervention. Of those, median time to reintervention was 9.1 months, including redo-TEVAR/extension in 32%, ascending/arch repair in 24%, open thoracoabdominal aortic repair in 56%, and false lumen embolization in 16%. Open conversions and reintervention were most likely to occur within the first year, with freedom of open conversion of 67.2% at 1 year, and 59.7% at 2 and 3 years, and freedom of reintervention of 49.8%, 36.0%, and 30.0% at 1, 2, and 3 years, respectively. CONCLUSIONS: This study suggests that TEVAR for patients with CTD can be performed safely; however, patients are at high risk for aortic-related morbidities and reintervention. Reinterventions and open conversion are common and more likely to occur within 1 year. TEVAR should remain limited in this population until more durable outcomes are possible.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Cass BD, Hanak CR, Ellis RC, et al. Thoracic endovascular aortic repair in connective tissue disease patients is not a definitive option. J Vasc Surg. 2024. PMID: 39617078. doi:10.1016/j.jvs.2024.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。